Despite decades of laboratory, epidemiological and clinical research, breast cancer
incidence continues to rise. Breast cancer remains the leading cancer-related cause of …

Triple-negative breast cancer accounted for 12% of breast cancers diagnosed in the United
States from 2012 to 2016, with a 5-year survival 8% to 16% lower than hormone receptor …

In this article, the American Cancer Society provides an overview of female breast cancer
statistics in the United States, including data on incidence, mortality, survival, and screening …

Between the years 2010 and 2012, the lifetime probability of developing female breast
cancer was 12.3%, or approximately 1 in 8. Worldwide, breast cancer is the most common …

In this article, the American Cancer Society provides the estimated number of new cancer
cases and deaths for blacks in the United States and the most recent data on cancer …

Gene-expression profiling has had a considerable impact on our understanding of breast
cancer biology. During the last 15 years, 5 intrinsic molecular subtypes of breast cancer …

Purpose Triple-negative breast cancer (TNBC) is a heterogeneous group of tumors
comprising various breast cancers simply defined by the absence of estrogen receptor …

Abstract Purpose The current American Joint Committee on Cancer (AJCC) staging manual
uses tumor size, lymph node, and metastatic status to stage breast cancer across different …

Triple-negative breast cancer constitutes a heterogeneous group of malignancies that are
often aggressive and associated with a poor prognosis. Molecular characterization, while …

Abstract Background In 2010, Surveillance, Epidemiology, and End Results (SEER)
registries began collecting human epidermal growth factor 2 (HER2) receptor status for …